FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308365137> ?p ?o ?g. }

• W4308365137 endingPage "898" @default.
• W4308365137 startingPage "888" @default.
• W4308365137 abstract "This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody-targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti-PD-(L)1 therapy.Patients with solid tumors, refractory to anti-PD-(L)1-based therapy, received intravenous FS118 weekly with an accelerated dose titration design (800 μg to 0.3 mg/kg) followed by 3+3 ascending dose expansion (1 to 20 mg/kg). Primary objectives were safety, tolerability, and PK. Additional endpoints included antitumor activity, immunogenicity, and pharmacodynamics.Forty-three patients with a median of three prior regimens in the locally advanced/metastatic setting, including at least one anti-PD-(L)1 regimen, received FS118 monotherapy. FS118 was well tolerated, with no serious adverse events relating to FS118 reported. No dose-limiting toxicities (DLT) were observed, and an MTD was not reached. The recommended phase 2 dose of FS118 was established as 10 mg/kg weekly. The terminal half-life was 3.9 days. Immunogenicity was transient. Pharmacodynamic activity was prolonged throughout dosing as demonstrated by sustained elevation of soluble LAG-3 and increased peripheral effector cells. The overall disease control rate (DCR) was 46.5%; this disease control was observed as stable disease, except for one late partial response. Disease control of 54.8% was observed in patients receiving 1 mg/kg or greater who had acquired resistance to PD-(L)1-targeted therapy.FS118 was well tolerated with no DLTs observed up to and including 20 mg/kg QW. Further studies are warranted to determine clinical benefit in patients who have become refractory to anti-PD-(L)1 therapy. See related commentary by Karapetyan and Luke, p. 835." @default.
• W4308365137 created "2022-11-11" @default.
• W4308365137 creator A5003061336 @default.
• W4308365137 creator A5012470359 @default.
• W4308365137 creator A5022467575 @default.
• W4308365137 creator A5026393942 @default.
• W4308365137 creator A5030816547 @default.
• W4308365137 creator A5049523132 @default.
• W4308365137 creator A5057733131 @default.
• W4308365137 creator A5058393482 @default.
• W4308365137 creator A5062344802 @default.
• W4308365137 creator A5064885286 @default.
• W4308365137 creator A5064953304 @default.
• W4308365137 creator A5065258693 @default.
• W4308365137 creator A5065685604 @default.
• W4308365137 creator A5068091975 @default.
• W4308365137 creator A5068368047 @default.
• W4308365137 creator A5073012449 @default.
• W4308365137 creator A5076265076 @default.
• W4308365137 creator A5076724473 @default.
• W4308365137 creator A5077814744 @default.
• W4308365137 creator A5078537913 @default.
• W4308365137 creator A5079225730 @default.
• W4308365137 creator A5086961491 @default.
• W4308365137 date "2022-11-09" @default.
• W4308365137 modified "2023-10-13" @default.
• W4308365137 title "A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance" @default.
• W4308365137 cites W1980897648 @default.
• W4308365137 cites W1981291019 @default.
• W4308365137 cites W1983188536 @default.
• W4308365137 cites W1984545852 @default.
• W4308365137 cites W1988474688 @default.
• W4308365137 cites W2041143310 @default.
• W4308365137 cites W2092830781 @default.
• W4308365137 cites W2100086637 @default.
• W4308365137 cites W2108565475 @default.
• W4308365137 cites W2139591061 @default.
• W4308365137 cites W2329974159 @default.
• W4308365137 cites W2414977199 @default.
• W4308365137 cites W2467554648 @default.
• W4308365137 cites W2468576628 @default.
• W4308365137 cites W2527850257 @default.
• W4308365137 cites W2544675721 @default.
• W4308365137 cites W2587048937 @default.
• W4308365137 cites W2593111137 @default.
• W4308365137 cites W2597811717 @default.
• W4308365137 cites W2754555242 @default.
• W4308365137 cites W2762500339 @default.
• W4308365137 cites W2763833329 @default.
• W4308365137 cites W2787624638 @default.
• W4308365137 cites W2890039677 @default.
• W4308365137 cites W2890398072 @default.
• W4308365137 cites W2904276001 @default.
• W4308365137 cites W2912137016 @default.
• W4308365137 cites W2982786601 @default.
• W4308365137 cites W3014748351 @default.
• W4308365137 cites W3016275977 @default.
• W4308365137 cites W3023611224 @default.
• W4308365137 cites W3042559121 @default.
• W4308365137 cites W3097017919 @default.
• W4308365137 cites W3118849389 @default.
• W4308365137 cites W3136616749 @default.
• W4308365137 cites W3166392727 @default.
• W4308365137 cites W3176510814 @default.
• W4308365137 cites W3202861314 @default.
• W4308365137 cites W4214685750 @default.
• W4308365137 cites W4225394054 @default.
• W4308365137 doi "https://doi.org/10.1158/1078-0432.ccr-22-1449" @default.
• W4308365137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342102" @default.
• W4308365137 hasPublicationYear "2022" @default.
• W4308365137 type Work @default.
• W4308365137 citedByCount "9" @default.
• W4308365137 countsByYear W43083651372021 @default.
• W4308365137 countsByYear W43083651372022 @default.
• W4308365137 countsByYear W43083651372023 @default.
• W4308365137 crossrefType "journal-article" @default.
• W4308365137 hasAuthorship W4308365137A5003061336 @default.
• W4308365137 hasAuthorship W4308365137A5012470359 @default.
• W4308365137 hasAuthorship W4308365137A5022467575 @default.
• W4308365137 hasAuthorship W4308365137A5026393942 @default.
• W4308365137 hasAuthorship W4308365137A5030816547 @default.
• W4308365137 hasAuthorship W4308365137A5049523132 @default.
• W4308365137 hasAuthorship W4308365137A5057733131 @default.
• W4308365137 hasAuthorship W4308365137A5058393482 @default.
• W4308365137 hasAuthorship W4308365137A5062344802 @default.
• W4308365137 hasAuthorship W4308365137A5064885286 @default.
• W4308365137 hasAuthorship W4308365137A5064953304 @default.
• W4308365137 hasAuthorship W4308365137A5065258693 @default.
• W4308365137 hasAuthorship W4308365137A5065685604 @default.
• W4308365137 hasAuthorship W4308365137A5068091975 @default.
• W4308365137 hasAuthorship W4308365137A5068368047 @default.
• W4308365137 hasAuthorship W4308365137A5073012449 @default.
• W4308365137 hasAuthorship W4308365137A5076265076 @default.
• W4308365137 hasAuthorship W4308365137A5076724473 @default.
• W4308365137 hasAuthorship W4308365137A5077814744 @default.
• W4308365137 hasAuthorship W4308365137A5078537913 @default.
• W4308365137 hasAuthorship W4308365137A5079225730 @default.
• W4308365137 hasAuthorship W4308365137A5086961491 @default.

• next